Group 1 - The board of directors of Shanghai United Imaging Healthcare Co., Ltd. held its 22nd meeting on August 25, 2025, with all 9 directors participating in the voting [1] - The meeting approved the adjustment of the initial grant price for the 2025 restricted stock incentive plan from 95 yuan per share to 94.92 yuan per share, with a unanimous vote of 9 in favor [2] - The board also approved the initial grant of 4.4713 million restricted shares to 1,368 incentive targets, with the grant date set for August 25, 2025, at the adjusted price of 94.92 yuan per share [3]

Core Viewpoint - Shanghai United Imaging Healthcare Co., Ltd. has received a medical device registration certificate for its photon-counting spectral CT, marking a significant breakthrough in China's medical technology sector and making it the first Chinese company to commercialize this technology globally [1][2]. Group 1: Product Development and Innovation - The photon-counting spectral CT, named uCT Ultima, is the first of its kind developed in China, representing a major advancement in the "14th Five-Year Plan" national key research and development project [1][2]. - The company has collaborated with several institutions, including Fudan University Zhongshan Hospital and Shanghai Jiao Tong University School of Medicine, to leverage their strengths in machine development, clinical application, and testing for the photon-counting spectral CT [2]. Group 2: Market Presence and Regulatory Approvals - The company has registered its products in over 80 countries and regions globally, with more than 140 products approved for market, including 53 that received FDA 510(k) certification and 57 that obtained EU CE marking [3]. - Recent flagship products include the uMR Ultra MRI system, the uCT SiriuX dual-source CT system, and the uAngio AVIVA zero-noise DSA system, which have set new standards in their respective categories [3]. Group 3: Strategic Impact - The acquisition of the medical device registration certificate will enhance the company's product variety, catering to diverse clinical needs and strengthening its core competitiveness [4].

Financial Performance - Northern Rare Earth reported a revenue of 18.8666 billion yuan for the first half of 2025, a year-on-year increase of 45.24%, with a net profit of 931 million yuan, up 1951.52% [2] - Aerospace Science and Technology achieved a revenue of 2.951 billion yuan, a year-on-year decrease of 11.04%, while net profit reached 88.97 million yuan, an increase of 2161.91% [2] - Other companies reported significant net profit growth, including: - Haohua Cement: 31% increase - Dongshan Precision: 35% increase - Daikin Heavy Industries: 214.32% increase - Shenzhen Huachang: 33.45% increase - Binjiang Group: 58.87% increase - Shen Nong Group: 212.65% increase - Dongxing Securities: 42.12% increase - Others with varying growth rates [9] Corporate Actions - Biyi Micro announced plans to acquire 100% equity of Shanghai Xingan Semiconductor for 295 million yuan, aiming to enhance its core business and technology capabilities [4] - Nanjing New Pharmaceutical signed an acquisition agreement to purchase a group of assets from Future Pharmaceutical for up to 480 million yuan, which is expected to constitute a major asset restructuring [8] - Dongzhu Ecology is planning to acquire control of Kairuixingtong, leading to a stock suspension [11] Regulatory and Compliance - Zhejiang Wen Film announced that independent director Liu Jing has been placed under detention by relevant supervisory authorities, but the matter is unrelated to the company [3] - Lianying Medical received a medical device registration certificate for its self-developed photon counting spectral CT, marking a significant breakthrough in medical technology [6] Market Developments - Cambridge Technology clarified that it currently does not produce chips with CPO technology, and its related business is still in the research and design phase, contributing minimally to current revenue [5]

证券代码：688271 证券简称：联影医疗 公告编号：2025-034 1、2025 年 6 月 13 日，公司召开第二届董事会第二十一次会议，会议审议 通过了《关于公司<2025 年限制性股票激励计划（草案）>及其摘要的议案》《关 于公司<2025 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股 东会授权董事会办理公司 2025 年限制性股票激励计划相关事宜的议案》。相关 事项已经过董事会薪酬与考核委员会审议通过。 上海联影医疗科技股份有限公司关于调整 公司 2025 年限制性股票激励计划首次授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票首次授予价格由 95.00 元/股调整为 94.92 元/股。 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2025 年 8 月 25 日召开第二届董事会第二十二次会议，会议审议通过了《关于调 整公司 2025 年限制性股票激励计划首次授予价格的议案》，同意董事会根据《上 市公司股权激励管理办法》（以下简称"《 ...

证券代码：688271 证券简称：联影医疗 公告编号：2025-035 上海联影医疗科技股份有限公司 关于向公司 2025 年限制性股票激励计划激励对象 首次授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票首次授予日：2025 年 8 月 25 日； 限制性股票首次授予数量：447.13 万股，约占目前公司股本总额 82,415.80 万股的 0.54%； 限制性股票首次授予价格：94.92 元/股； 股权激励方式：第二类限制性股票。 《上海联影医疗科技股份有限公司 2025 年限制性股票激励计划》（以下简称 "《激励计划》"或"本激励计划"）规定的限制性股票授予条件已经成就，根据 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）2024 年年 度股东会的授权，公司于 2025 年 8 月 25 日召开第二届董事会第二十二次会议， 审议通过了《关于向公司 2025 年限制性股票激励计划激励对象首次授予限制性 股票的议案》，同意以 2025 年 8 月 25 日为 ...

上海联影医疗科技股份有限公司 1、公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过本激励计划草案公告 时公司股本总额的 20%。本激励计划中任何一名激励对象通过全部在有效期内的股权激励计划获授 的公司股票数量累计未超过公司股本总额的 1%。 2、本激励计划拟授予激励对象不包括独立董事。 3、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 上海联影医疗科技股份有限公司董事会 2025 年 8 月 25 日 | 姓名 | 国籍 | 职务 | 获授的限制 | 占授予限制 | 占授予时公司股 | | --- | --- | --- | --- | --- | --- | | | | | 性股票数量 （万股） | 性股票总数 的比例 | 本总额的比例 | | 一、首次授予部分 | | | | | | | 1、董事、高级管理人员、核心技术人员 | | | | | | | 王建保 | 中国 | 财务负责人、首席财务官 | 20 | 4.00% | 0.02% | | 胡玮 | 中国 | 核心技术人员 | 0.8 | 0.16% | 0.001% | | 2、其他激励对象 | | | | ...

68 Yin Chena Road Mic 上海市通力律师事务所关于上海联影医疗科技股份有限公司 2025 年限制性股票激励计划调整及首次授予事项的法律意见书 致:上海联影医疗科技股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受上海联影医疗科技股份有限公司(以下简 称"联影医疗"或"公司")委托,指派本所朱晓明律师、夏青律师(以下合称"本所律师") 担任公司 2025 年限制性股票激励计划(以下简称"本次股权激励计划")的专项法律顾问,根 据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、中国证券监督管理委员会(以下简称"中国证监会")发布的《上 市公司股权激励管理办法》(以下简称"《管理办法》")等法律、行政法规和其他规范性文 件(以下简称"法律、法规和规范性文件")以及《上海联影医疗科技股份有限公司章程》(以 下简称"《公司章程》")以及《2025年限制性股票激励计划》(以下简称"《激励计划》") 的有关规定,就本次股权激励计划首次授予价格调整(以下简称"本次调整")及首次授予(以 下简称"本次授予")相关事项出具法律意见。 为出 ...

截至发稿，联影医疗市值为1125亿元。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 （记者 曾健辉） 每日经济新闻 每经AI快讯，联影医疗（SH 688271，收盘价：136.5元）8月26日晚间发布公告称，公司第二届第二十 二次董事会临时会议于2025年8月25日在公司会议室召开。会议审议了《关于调整公司2025年限制性股 票激励计划首次授予价格的议案》等文件。 2024年1至12月份，联影医疗的营业收入构成为：医疗器械行业占比95.96%，其他业务占比4.04%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

Group 1 - The core point of the article is that United Imaging Healthcare has received a medical device registration certificate for its photon counting spectral CT from the National Medical Products Administration, indicating a significant advancement in its product offerings [1] - For the fiscal year 2024, United Imaging Healthcare's revenue composition is heavily weighted towards the medical device sector, accounting for 95.96% of total revenue, while other business segments contribute only 4.04% [1] - As of the report, United Imaging Healthcare has a market capitalization of 112.5 billion yuan [1]

Group 1 - The State Council emphasizes increasing financial and fiscal support for the artificial intelligence (AI) sector, aiming for over 70% penetration of new intelligent terminals and agents by 2027 [2][3] - By 2030, AI is expected to significantly contribute to high-quality economic development, with over 90% penetration of new intelligent applications [2] - The government plans to enhance the legal and regulatory framework for AI, including risk management and investment exit mechanisms [2][4] Group 2 - The National Development and Reform Commission (NDRC) will coordinate efforts to implement the AI action plan, ensuring local adaptation and avoiding superficial compliance [4] - The NDRC aims to foster a complete AI application service chain and promote the development of intelligent native technologies and services [4] - The NDRC will also support open-source ecosystem development to enhance international influence [4] Group 3 - The National Energy Administration acknowledges that the rapid growth of electric vehicle and AI sectors is driving increased electricity demand, which is reshaping energy consumption patterns [5][6] - Data indicates a 34.3% year-on-year increase in electricity consumption for new energy vehicle manufacturing in 2024, and a 20.5% increase for internet and related services [5][6] Group 4 - The new generation of the Chinese operating system, Galaxy Kirin V11, has been officially released, featuring significant improvements in architecture, security, and ecosystem compatibility [6] - Galaxy Kirin has achieved over 16 million deployments and is compatible with major domestic CPUs and GPUs, supporting various national projects [6] Group 5 - ByteDance has raised its option price to $200.41 per share, marking a significant increase from $189.9 earlier this year, reflecting a fivefold increase since 2019 [6] Group 6 - Aliyun's Baolian has announced a price reduction for certain model context caching, lowering the cost from 40% to 20% of the input token price when cache hits occur [7] Group 7 - Union Medical has received a medical device registration certificate for China's first photon counting spectral CT, marking a significant advancement in medical technology [8] - Nanjing New Pharmaceutical plans to acquire assets from Future Medicine for up to 480 million yuan, which is expected to constitute a major asset restructuring [9] - Biyimi plans to acquire 100% of Shanghai Xingan Semiconductor for 295 million yuan to enhance its core business and technology capabilities [10]